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Abstract
Background: Our laboratory and others reported that the stimulation of specific Toll-like receptors (TLRs) affects the
immune modulating responses of human multipotent mesenchymal stromal cells (hMSCs). Toll-like receptors recognize
‘‘danger’’ signals, and their activation leads to profound cellular and systemic responses that mobilize innate and adaptive
host immune cells. The danger signals that trigger TLRs are released following most tissue pathologies. Since danger signals
recruit immune cells to sites of injury, we reasoned that hMSCs might be recruited in a similar way. Indeed, we found that
hMSCs express several TLRs (e.g., TLR3 and TLR4), and that their migration, invasion, and secretion of immune modulating
factors is drastically affected by specific TLR-agonist engagement. In particular, we noted diverse consequences on the
hMSCs following stimulation of TLR3 when compared to TLR4 by our low-level, short-term TLR-priming protocol.
Principal Findings: Here we extend our studies on the effect on immune modulation by specific TLR-priming of hMSCs, and
based on our findings, propose a new paradigm for hMSCs that takes its cue from the monocyte literature. Specifically, that
hMSCs can be polarized by downstream TLR signaling into two homogenously acting phenotypes we classify here as MSC1
and MSC2. This concept came from our observations that TLR4-primed hMSCs, or MSC1, mostly elaborate pro-inflammatory
mediators, while TLR3-primed hMSCs, or MSC2, express mostly immunosuppressive ones. Additionally, allogeneic co-
cultures of TLR-primed MSCs with peripheral blood mononuclear cells (PBMCs) predictably lead to suppressed T-
lymphocyte activation following MSC2 co-culture, and permissive T-lymphocyte activation in co-culture with MSC1.
Significance: Our study provides an explanation to some of the conflicting reports on the net effect of TLR stimulation and
its downstream consequences on the immune modulating properties of stem cells. We further suggest that MSC
polarization provides a convenient way to render these heterogeneous preparations of cells more uniform while
introducing a new facet to study, as well as provides an important aspect to consider for the improvement of current stem
cell-based therapies.
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Introduction
Multipotent mesenchymal stromal cells (formerly known as
mesenchymal stem cells, MSCs) are readily separated from other
bone marrow-derived cells by their tendency to adhere to plastic.
MSCs differentiate into osteoblasts, chondrocytes, and adipocytes
under appropriate culture conditions [1–4]. Further, they offer the
advantage that they are easily expanded and stored ex vivo and are
considered to be ‘‘immunoprivileged.’’ Thus, once harvested they
can safely be infused into either autologous or allogenous hosts
owing to their lack of host immune reactivity [2]. These cells home
to damaged tissues and contribute to their repair by secretion of
cytokines, chemokines, and extracellular matrix proteins [3,5]. As
a result of these qualities, MSCs are very attractive candidates in
stem cell-based strategies for tissue repair and gene therapy.
Numerous investigators have now demonstrated the successful
recruitment and multi-organ engraftment capability of infused
MSCs in various animal models and human clinical trials [6–10].
However, the precise molecular mechanisms governing stem cell
fate, mobilization, and recruitment to the sites of engraftment are
not fully understood. Additionally, even though there is a clear
clinical benefit observed when MSCs have been used in cell-based
therapy, few infused cells (0.1–1%) have been found at the target
site [2,11,12]. This observation has prompted investigators to
suggest that the benefit observed is due to local immune
modulation by these cells rather than by differentiation or
replacement of the damaged target tissue by the infused stem
cells [9–11].
Our laboratory and others established a connection between the
stimulation of specific Toll-like receptors (TLRs) and the immune
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cells (hMSCs) [13–15]. Toll-like receptors recognize ‘‘danger’’
signals and their activation leads to profound cellular and systemic
responses that mobilize innate and adaptive host immune cells
[16–20]. The TLRs consist of a large family of evolutionarily
conserved receptors (e.g.-TLR1-9). The danger signals that trigger
TLRs are released following most tissue pathologies. Exogenous
danger signals typically released after microbial infections are
exemplified by endotoxin or lipopolysaccharide (LPS) sheddings.
Endogenous danger signals spilled into the circulation from
aberrant or wounded cells are characterized by intracellular
components like heat shock proteins or RNA. Typically, these
shed danger signals activate TLRs on sentinel innate immune cells
(e.g.-dendritic cells), and start an appropriate host response that re-
establishes homeostasis [16–19]. Since danger signals recruit
immune cells to sites of injury we reasoned that hMSCs might
employ the same mechanisms to find the tissues in need of their
reparative mission. Surprisingly, we found that not only did
hMSCs express several TLRs but also that their capability to
migrate, invade, and secrete immune modulating factors was
drastically affected by specific TLR-agonist engagement [15]. In
particular, we observed that TLR3 stimulation leads to the
secretion of factors with mostly immune suppressive properties,
while stimulation of TLR4 with LPS resulted in the secretion of
more pro-inflammatory factors.
Other investigations have evaluated the effects of TLR
engagement on the typical stromal stem cell properties of tri-lineage
differentiation (chondrogenic, osteogenic, adipogenic) and prolifer-
ation. For instance, Hwa Cho et al. described a role for TLRs in
proliferation and differentiation of human adipose-derived stem
cells (hADSCs) [13]. In another report, murine MSC (muMSCs)
were found to express TLRs that upon activation affected their
proliferation and differentiation [14]. However, in contrast to
hMSCs, they suggested that activation of TLR2 inhibits both
differentiation and migration of muMSCs while promoting their
proliferation. Liotta et al. found no effect of TLR activation on
adipogenic, osteogenic, or chondrogenic differentiation in hMSCs
[21]. Further, in contrast to our study, their report suggested
equivalent roles for TLR3 and TLR4 engagement in hMSC
immunemodulation.Recently,Lombardo etal.reported that TLR3
and TLR4 engagement within hADSCs increased osteogenic
differentiation but had no effect on their adipogenic differentiation
or proliferation [22]. They also concluded that TLR2, TLR3, and
TLR4 ligation does not affect hADSCs ability to suppress
lymphocyte activation, in contrast to the Liotta et al. report.
The recently described immune modulating properties of these
cells appear to be rather complex. For instance, immune
modulation by hMSCs is attributed to not only secretion of
soluble factors but is also dependent on MSC-to-immune cell
contact [23]. MSCs express low levels of human leukocyte antigen
(HLA) major histocompatibility complex (MHC) class I, do not
express co-stimulatory molecules (B7-1, -2, CD40, or CD40L), and
can be induced to express MHC class II and Fas ligand explaining
why they do not activate alloreactive T cells. MSCs inhibit
dendritic cell (DC) maturation, B and T cell proliferation and
differentiation, as well as attenuate natural killer (NK) cell killing,
and also support suppressive T regulatory cells (Tregs) [3,23–26].
Several factors have been associated with these immune
modulating properties of MSCs, including transforming growth
factor beta (TGFb), hepatocyte growth factor (HGF), HLA-G,
prostaglandin (PGE2), IL-10, indoleamine 2,3-dioxygenase (IDO),
and interferon-gamma (IFNc) [3,27–33]. More recently a role for
the notch family member Jagged1 in immune modulation was
specifically attributed to downstream TLR signaling of MSCs [21].
Whis this in mind, an explanation for the contrasting and
complex immune modulating effects reported thus far for TLR
activation in most stem cells may lie in reinterpretation of all of the
data taking into account the fact that most of the current stem cell
preparations yield heterogeneous pools of cells, as well as
acknowledging that TLRs expressed on different cell types and
from different species (mouse and man) do not always have the
same responses [34,35]. Other important contributing factors that
may account for the conflicting reports in the TLR responses of
stem cells are the concentration and length of incubation with the
specific TLR agonist, along with careful attention and safeguard-
ing to common LPS (TLR4 agonist) contamination in the
laboratory.
Here, we extended our studies on TLRs and immune
modulation by hMSCs to provide some support for these concepts
and build on our initial observations that low-level, short-term
stimulation with specific TLR3 and TLR4 agonists (or TLR-
priming) within hMSCs mediates distinct immune modulating
responses. It is established that stimulation of monocytes with
known cytokines or agonists to their TLRs, like interferon-c- and
endotoxin (LPS, TLR4-agonist), polarizes them into a classical M1
phenotype that participate in early pro-inflammatory responses,
while IL-4 treatment of monocytes yields the alternate M2
phenotype that is associated with later anti-inflammatory resolu-
tion responses [36]. We introduce a new aspect of hMSC biology
implied by this work, that suggests that hMSCs, like monocytes,
are polarized by downstream TLR signaling into two homo-
genously acting phenotypes we classify here as MSC1 and MSC2,
following the monocyte nomenclature. We suggest that hMSCs
respond in a manner analogous to monocytes following specific
TLR priming that ultimately will help make MSC preparations
more uniform, and will be important to study and consider in
future improved designs of stem cell-based therapies [36–38].
Results
Cytokine and chemokine secretion patterns following
TLR3 or TLR4 activation of hMSCs are consistent with
divergent immune modulating effects by these agonists
In this study, we set out to extend our previous observations of
the effect that TLR signaling has on the immune modulating
property of hMSCs, as well as to potentially provide an
explanation for the contrasting reports in this field [15]. In the
experiments included here, we typically used a TLR-priming
protocol that is defined as the incubation with LPS (10 ng/mL) or
poly(I:C) (1 mg/mL) added as the hMSCs agonists for TLR4 and
TLR3, respectively, for no longer than 1 hr prior to washing and
further 24–48 hr incubation in growth medium [15]. The short
incubation time (,1 hr) and minimal TLR agonist concentrations
used here are postulated to mimic the gradient of danger signals
endogenous MSCs encounter and respond to at a distance from
the site of injury. The conditioned medium was collected and
analyzed with Bio-Plex Cytokine Assays (Human Group I & II).
Consistent with our published results, TLR3 stimulation in
hMSCs led to elevated secretion of certain immune modulating
factors different from those elaborated by TLR4 activation in
hMSCs (Fig. 1A)[3]. To provide further support for the specific
effects by each of these receptors, hMSCs were transfected with
dominant negative plasmids for each of the TLR-receptors, and
the factors secreted were once again measured by BioPlex assay.
This strategy corroborated the TLR3-driven effect on hMSC
secretion of CCL10 (IP-10), CCL5 (RANTES), and to a lesser
degree IL4 and IL10. It appeared that TLR4 signaling is upstream
of IL6 and IL8 as shown in Fig. 1B.
TLR Polarization of MSCs
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migration and invasion capabilities of the treated hMSCs
Apart from the distinct effects of TLR3 and TLR4 activation on
cytokine/chemokine secretion we also initially reported that TLR
activation promoted hMSC migration, while Pevsner-Fischer et al.
reported that in murine MSCs TLR activation inhibited the
migration of these cells [14]. The hMSC migration assays were
performed again with varying incubation times and stimulants to
gain a better understanding of this process within hMSCs, and
taking into consideration a related report stating that CCL5
(RANTES) driven hMSC migration was highly induced by pre-
treatment of the hMSCs with TNFa [39]. Thus, the migration by
the TLR-primed hMSCs was analyzed following initial exposure
to LPS (TLR4 ligand), poly(I:C) (TLR3 ligand), CCL5, or TNFa
for an hour or 24 hr prior to loading the cells on the top chamber
for the transwell migration assays (Fig. 2)[15]. Stimulation for 1 hr
of TLR3 and TLR4 within hMSCs promoted migration and
invasion towards 16.5% serum containing medium when com-
pared to untreated samples, as previously reported [15]. However,
24 hr incubation with these ligands suppressed migration and
invasion of the treated hMSCs. By contrast, this longer incubation
time was essential for CCL5 and TNFa driven migration and
invasion by the hMSCs. Inhibition of the expression of TLR3 and
TLR4 receptors by nucleofection with knockdown plasmids
diminished migration by .50% in unprimed hMSCs, consistent
with our previous report [15]. However, LPS or poly(I:C)
treatment of the transfected cells resulted in greater migration
when compared with unstimulated controls (data not shown). We
speculate that the stress of nucleofection and/or the endogeneous
inhibition of the TLR receptors may derepress a TLR-associated
inhibitor of migration—and thus enhance rather than suppress the
migration of transfected hMSCs as we expected. It appears that
migration and invasion mechanisms driven by TLRs within
hMSCs are more complex than originally appreciated.
Varying effects of TLR3 and TLR4 stimulation on hMSCs
adipogenic and osteogenic differentiation potential
Next, given the reported differences on the effect that TLR3
and TLR4 activation have on the tri-lineage (cartilage, bone, fat)
differentiation capabilities of hMSCs, we also measured these
using our particular methods of TLR activation with reduced
amounts of TLR ligand when compared to most other studies
[13,14,22]. The hMSCs were simultaneously induced to differen-
tiate in the constant presence of TLR3 (1 mg/mL poly(I:C)) and
TLR4 agonists (10 ng/mL LPS) maintained for the duration of
the differentiation assays in the inductive medium. By this method,
we noted an inhibition of all bone, fat, or cartilage (not shown)
programs after TLR3 activation of hMSCs (Fig. 3). Simultaneous
TLR4 activation of hMSCs inhibited adipogenesis, stimulated
osteogenesis, and did not affect chondrogenesis (not shown).
hMSCs deposit more fibronectin following TLR3
activation, and more collagen when TLR4 is stimulated
Since we had thus far seen distinct effects of TLR activation
within hMSCs and their secretion of cytokines/chemokines and
differentiation, it was of interest to study whether these different
Figure 1. MSC1 differ from MSC2 in their secretion of immune modulators. A. The data show increased expression of known
immune suppressive factors by TLR3-primed hMSCs (MSC2) but not by TLR4-primed hMSCs (MSC1). Methods: MSCs were pre-treated
for 1 hr with TLR agonists (LPS for MSC1 or poly(I:C) for MSC2), washed and cultured for an additional 48 hr prior to harvesting the spent medium and
analysis with Bio-Plex Cytokine Assays (Human Group I & II; Bio-Rad, Hercules, CA) following the manufacturer’s instructions. Data are presented by
the quantitative comparative CT (threshold value) method [46]. Error bars indicate SEM. Data are representative of triplicate measurements with 5
MSC donors. B. The data implicate direct TLR3 induction of IP10 (CCL10) and RANTES (CCL5) secretion. Methods: hMSCs were transfected
with pZERO-hTLR3 and pZERO-hTLR4 (Invivogen), using 250 ng plasmid/1610
6 cells (nucleofector). Cells from each transfection were left untreated
or stimulated with TLR3 and TLR4 agonists for 1 hr washed and incubated for 48 hr. Conditioned medium was harvested and analyzed as in A.
Transfection efficiency was determined by these methods to be 30–35%. Data are representative of triplicate measurements with 3 MSC donors.
doi:10.1371/journal.pone.0010088.g001
TLR Polarization of MSCs
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extracellular matrix deposition. The hMSCs were grown on
chamber slides to 70% confluence primed for 1 hr with TLR3-
and TLR4-agonists as before, washed and incubated further for
24 hr prior to fixation. ECM antibody staining was performed
following fixation and membrane permeabilization of the TLR-
primed hMSCs seeded on chamber slides (Fig. 4). As a control, the
primary antibody was omitted from staining procedure (data not
shown). Densitometric analysis revealed that TLR3 stimulation of
hMSCs resulted in diminished collagen I/II deposition when
compared to unprimed or TLR4 stimulated hMSCs. This
treatment also resulted in greater than two-fold fibronectin
deposition when compared to unprimed or TLR4 stimulated
hMSCs (Fig. 4B). Interestingly, integrin-linked kinase (ILK) and
von Hippel-Lindau protein (VHL), which are also associated with
ECM deposition mechanisms, are also differentially expressed
after TLR-stimulation. TLR3-stimulation of hMSCs increased the
expression of both ILK and VHL, whereas TLR4-stimulation
dampened their expression (data not shown).
Transforming growth factor b (TGF)1,3 secretion is
repressed by TLR3 but not TLR4 stimulation of hMSCs
TGFb secretion by hMSCs was measured from the conditioned
medium after TLR3 and TLR4 priming, as before (Fig. 5). We
were interested in this family of factors, since TGFb is known to
mediate elevated collagen deposition as supported by our TLR4-
priming results above, and it is also a known immune modulating
factor [40,41]. TGFb1, 2, and 3 were measured from the spent
culture medium by luminex immunoassay as per manufacturer’s
recommendations (LINCOplex from Millipore). The TLR-primed
hMSCs were washed and cultured for an additional 48 hr prior to
harvesting the spent medium for TGFb detection. TLR3
activation of hMSCs considerably reduced (.65–80%) secretion
of TGFb1 and 3. The levels measured for TGFb2 secretion were
small for all samples (5 pg/mL), and were reduced by both
treatments (,1 pg/mL, data not shown). As expected, TLR4
Figure 2. Short-term TLR stimulation promotes the migration of hMSCs. Data show that short-term TLR-priming stimulates
migration. By contrast, 24 hr incubation is needed for enhanced migration by CCL5 (RANTES) and TNFa treatment. Methods: hMSCs
migration was examined by transwell migration assay after pre-incubation with TLR-ligands, CCL5 (150 ng/mL), or TNFa (1 ng/mL) for either 1 or
24 hr prior to loading on Matrigel-coated inserts. After overnight incubation, migration towards the serum chemoattractant was visualized and
recorded by fluorescence microscopy. Migration was quantified from the obtained micrographs by counting the number of fluorescently-labeled
cells remaining after removal of non-migrating cells in triplicate wells. Bar graph of the obtained results normalized to unprimed cells. Error bars
indicate SEM. (n=6).
doi:10.1371/journal.pone.0010088.g002
Figure 3. TLR3 activation inhibits bone and fat differentiation.
TLR4 activation promotes bone differentiation and inhibits fat
differentiation in hMSCs. Methods: The hMSCs were induced (+)t o
differentiate in the presence of TLR3 and TLR4 ligands throughout the
four-week incubation period prior to staining for differentiation markers
by established methods. Untreated hMSCs (untx) were either induced
(+) or not and served as assay controls. (n.3)
doi:10.1371/journal.pone.0010088.g003
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samples for this parameter (data not shown).
The downstream TGFb effectors SMAD3 and SMAD7 are
differentially expressed by TLR3 and TLR4 priming of
hMSCs
The downstream TGFb effectors SMAD3 and SMAD7 that
might support the TGFb results presented above were measured
after TLR stimulation of hMSCs. The hMSCs were grown on
chamber slides to 70% confluence, pre-treated for 1 hr with TLR3
and TLR4 agonists, washed, and incubated further for 24 hr prior
to fixation. Fluorescently labeled SMAD3, phospho-SMAD3
(activated SMAD3), and SMAD7 antibodies were incubated with
the TLR-primed hMSCs as indicated (Fig. 6A & B). As a control,
the primary antibody was omitted from staining procedure (data
not shown). Densitometric analysis revealed that TLR3 stimula-
tion of hMSCs resulted in elevated SMAD7 expression, and
diminished and diffused nuclear phospho-SMAD3 and SMAD3,
whereas TLR4 stimulation led to increased focused nuclear
phosphoSMAD3 expression and reduced SMAD7 expression
when compared with untreated hMSCs. Flow cytometry analyses
of these markers supported these observations (data not shown).
Distinct effects are found by TLR3 and TLR4 stimulation
in the hMSCs on the expression of Jagged 1 and 2
We next measured Jagged 1 and 2 expression in TLR
stimulated hMSCs since these proteins have been linked to some
of the controversial reports on immunomodulation following TLR
activation of MSCs, and are also known to correlate with TGFb
signaling [21,42,43]. The hMSCs were grown on chamber slides
to 70% confluence, pre-treated for 1 hr with TLR3 and TLR4
agonists, washed, and incubated further for 24 hr prior to fixation.
Fluorescently labeled Jagged 1 and Jagged 2 antibodies were
incubated with the TLR-primed hMSCs, as indicated (Fig. 7). As a
control, the primary antibody was omitted from staining
procedure (data not shown). Jagged 1 and Jagged 2 expression
was diffuse in unprimed hMSCs. TLR3 stimulation of hMSCs
resulted in reduced and perinuclear Jagged 1 expression, and
unremarkable Jagged 2 expression. TLR4 stimulation led to
increased Jagged 1 expression that was found both perinuclear and
Figure 4. TLR3-primed hMSCs deposit more fibronectin, while TLR4-primed hMSCs deposit more collagen. A. Data demonstrate
that TLR4-primed cells deposit twice as much collagen I/II and half as much fibronectin as TLR3-primed cells. B. Densitometric
analysis of micrographs in A. left bars (grey) are collagen I/II and right bars (black) are fibronectin results normalized to
background absorbance. Methods: hMSCs were grown on chamber slides to 70% confluence pre-treated for 1 h with ligands: 1 mM poly(I:C)
(TLR3) or 10 ng/mL LPS (TLR 4) and incubated further for 24 hr prior to fixation. ECM antibody staining was performed following fixation and
membrane permeabilization of the TLR-primed or unprimed hMSCs seeded on chamber slides (antibodies from Chemicon International, CA, hu
fibronectin MAB1926 and collagen I/II MAB3391). As a control, the primary antibody was omitted from staining procedure (data not shown, n.6).
Densitometric analysis of the micrographs was performed with ImageJ software.
doi:10.1371/journal.pone.0010088.g004
TLR Polarization of MSCs
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characteristic endosomal distribution. Flow cytometry analyses of
these markers supported some of these observations as shown
below.
Indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2
(PGE2), other known mediators of hMSC immune
modulation, are also differently affected by TLR3 and
TLR4 priming
To lend further support for the observed dichotomy of hMSCs
immune modulation downstream from TLR3 and TLR4
stimulation, we also measured other known potentiators of hMSCs
immune modulation, IDO and PGE2, following the TLR3-and
TLR4 priming protocol [26,44]. IDO was measured by real-time
PCR analysis of RNA extracted from TLR-primed hMSCs
incubated further for 6 hr prior to RNA harvest. Data are
presented by the quantitative comparative CT (threshold value)
method (Fig. 8A)[45]. PGE2 was measured from the spent culture
medium after 1 hr TLR-agonist pretreatment, wash, and 48 hr of
subsequent culture by commercially available ELISA assays
(Fig. 8B). Consistent with the previous results, it appeared that
these immunosuppressive indicators are elevated following TLR3
(poly(I:C)) stimulation, and, in contrast, mostly unchanged by
TLR4 (LPS) activation of the hMSCs.
Arginase and HLA-G expression are other relevant immune
modulating effectors that were tested after TLR3 and TLR4
stimulation of hMSCs. These unfortunately gave inconclusive
results with the various methods attempted (data not shown).
Allogeneic co-culture of hMSCs and hPBMCs leads to T
cell activation only with TLR4 primed hMSCs but not
unprimed or TLR3 primed hMSCs
The immunosuppressive role of heterogeneous MSCs was
originally described from allogeneic co-cultures of MSCs with
PBMCs or isolated naı ¨ve T-cell preparations [3,31]. The addition
of unprimed MSC pools to alloreactive T-cells prevents their
activation and/or proliferation. Additionally, MSCs infused into
allogeneic hosts do not elicit host immune reactivity. This is largely
due to the fact that the unprimed MSCs express low levels of
human leukocyte antigen (HLA) major histocompatibility complex
(MHC) class I, do not express co-stimulatory molecules (B7.1/
CD80, B7.2/CD86, CD40, or CD40L), and can be induced to
express MHC class II and Fas ligand only upon interferon
treatment [3,32].
T-lymphocytes among human peripheral blood mononuclear
cells (hPBMCs, 10
6 from at least 5 unrelated donors, labeled), in
the presence or absence of the isolated TLR-primed MSCs or
unprimed MSCs, were resuspended and stimulated with 1 mgo f
CD3/CD28 antibody beads. After 72 hr, the cells were stained
with CD8- or CD4-antibody, and CFSE-label dilution of the
CD8+ cells was assessed by flow cytometry analysis. Data are
expressed as percent activation or change from the % T-
lymphocyte activation obtained for the activated hPBMCs not
co-cultured with hMSCs (Fig. 9)[3]. As previously reported,
incubation of unprimed hMSCs with hPBMCs considerably
reduced their activation to .90% [3]. However, TLR4 stimula-
tion inhibited this immune dampening effect by the hMSCs (back
to almost 100% activation), while TLR3 supported the immune
suppression (.90%). Based on these observations, we suggest that
TLR-priming effectively polarizes the hMSCs towards two distinct
phenotypes. TLR4-priming of hMSCs results in a pro-inflamma-
tory signature we refer to here as MSC1; whereas, TLR3-priming
supports an immune suppressive one we term MSC2. TLR4
activation of hMSCs also consistently resulted in twice as many
non-adherent cells recovered at the end of the experiment when
compared to the cells recovered from un-activated PBMCs,
unprimed hMSC, or TLR3-primed hMSC (Table 1).
The expression of various immune modulating factors was
measured from the spent co-culture medium at the end of the
experiment with BioPlex assays, as before [46]. The expression of
CCL5 and CCL10 followed the same patterns as above. Increased
secretion for these was observed in co-cultures with TLR3-primed
hMSCs when compared to unprimed or TLR4-primed cultures.
By contrast, IL6 and IL8 secretion was higher in the co-culture
medium of TLR4-primed cells when compared to the other two
groups (data not shown). Jagged 1 and SMAD7 expression within
co-cultured cells was measured by flow cytometry (Fig. 9D and E).
For the purpose of the analysis, CD45+ cells were considered
hPBMCs, and CD90+ adherent cells were considered hMSCs.
Jagged 1 expression was elevated in both the hPBMCs and hMSCs
populations harvested from TLR4-primed MSC co-cultures when
compared to unprimed cultures. SMAD7 expression in both was
elevated in TLR3-primed MSC co-cultures when compared to
unprimed cultures.
Discussion
It is now evident that Toll-like receptors (TLRs) are vital in
coordinating not only the pro-homeostatic tissue injury responses
of immune cells but also that of multipotent mesenchymal stromal
cells (MSCs) of various origins. In trying to tease out the molecular
details of TLR signaling within human MSCs (hMSCs), we
initially observed distinct effects after stimulation of TLR3 when
compared with TLR4 activation using our short-term, low-level
TLR priming protocol [15]. By use of this protocol in the study
presented here, TLR3 stimulation of hMSCs supports their
established immunosuppressive effects, while TLR4 activation of
hMSCs more consistently provides a pro-inflammatory signature.
From these observations, we propose a new paradigm for MSCs
that takes its cue from the monocyte literature, that these
heterogeneous cells can be induced to polarize into two diverse
but homogeneously acting phenotypes [36]. We also contend that
Figure 5. Transforming growth factorb (TGFb1 and 3) expres-
sion is diminished in TLR3-primed MSCs compared with
measured levels for TLR4-primed and unprimed MSCs. TGFb
2 levels are small but are further repressed by both treatments.
Methods: MSCs were pre-treated for 1 hr with TLR4 agonist (LPS for
MSC1) or TLR3 agonist (poly(I:C) for MSC2), washed, and cultured for an
additional 48 hr prior to harvesting the spent medium for TGFb
detection. TGFb 1, 2 & 3 were detected by luminex immunoassay
(LuminexH Bead immunoassay Kit, LINCOplex from Millipore). Data are
representative of triplicate measurements with 6 hMSC donors. Error
bars indicate SEM. *p,0.005 comparison to unprimed MSCs.
doi:10.1371/journal.pone.0010088.g005
TLR Polarization of MSCs
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stimulation within stem cells can be resolved by taking into
consideration the source of cells, their originating species, as well
as the time and concentration of TLR agonist exposure. In line
with this and the new MSC paradigm, we propose that short-term,
low-level exposure with TLR4 agonists polarizes hMSCs toward a
pro-inflammatory MSC1 phenotype important for early injury
responses. By contrast, the downstream consequences of TLR3
agonist exposure of hMSCs are its polarization toward an
immunosuppressive MSC2 phenotype essential to later anti-
inflammatory responses that help resolve the tissue injury. While
our findings that hMSCs can be pro-inflammatory challenge
current dogma, a recent report along with the work presented here
supports this allegation [47]. Romieu-Mourez et al. showed that
TLR stimulation in MSCs resulted in the formation of an
inflammatory site attracting innate immune cells in neutrophil
chemotaxis assays and by the analyses of immune effectors
retrieved from TLR-activated MSC microenvironments within
mice. We drew our conclusions based on the consistent but
different results observed for MSC1 when compared with MSC2
in the many parameters tested and presented. These include
dissimilar secretion of cytokines and chemokines (Tables S1 and
S2), and differences in differentiation capabilities, ECM deposi-
tion, TGFb signaling pathways, Jagged expression, IDO and
PGE2 expression, and finally polar opposite effects on T-
lymphocyte activation by MSC1 and MSC2.
We provide further support for TLR3 mediated elevated
secretion of CCL10 (IP10), CCL5 (RANTES), and IL10, since
this effect could be specifically inhibited by dominant-negative
TLR3 expression and not TLR4-dominant negative expression
(Fig. 1B). However, we found that the enhanced IL6 and IL8
expression after TLR-priming was downstream of both TLR3 and
TLR4 activation, and that the secretion of other soluble mediators
was indirectly affected by these since no direct effect was noted by
the dominant negative strategy (Fig. 1B-note IL4 and data not
shown). We add that all the siRNA-driven TLR3 inhibition
strategies we attempted were unsuccessful owing to the fact that
double stranded RNAs used as the interfering agent are most likely
also acting as the agonist for the targeted TLR3 receptor.
Inhibition of the expression of TLR3 and TLR4 receptors by
Figure 6. SMAD3 expression and activation (phosphoSMAD3, pSMAD3), as well as SMAD7 expression in hMSCs. A. Data show that
SMAD3 is activated in TLR4-primed (increased nuclear pSMAD3) but not TLR3-primed hMSCs. Yellow arrows point to
corresponding magnified cell nuclei. B. SMAD7 expression is induced after TLR3 but not TLR4 stimulation of hMSCs. Methods:
hMSCs were grown on chamber slides to 70% confluence, TLR-primed as before, and incubated further for 24 hr prior to fixation. SMAD3, SMAD7,
and phosphoSMAD3 antibody staining was performed as indicated in Methods. Representative micrographs of 5 tested hMSC donors.
doi:10.1371/journal.pone.0010088.g006
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luciferase expression by .90% (data not shown), along with the
effect on the soluble mediators. Next, we found that hMSC
migration is affected by both the stimulant and the time it is
exposed to it (Fig. 2). Whereas TLR-priming promoted hMSC
migration, the equivalent short-term exposure with TNFa and
CCL5 did not promote migration. Conversely, long-term TLR-
priming inhibited hMSC migration but was effective for TNFa
and CCL5 mediated migration. We suggest that the short-term,
low-level TLR-priming mimics the gradient of danger signals
endogenous MSCs encounter and respond to at a distance from
the site of injury that draws them to the appropriate target. Once
the hMSCs arrive at the site spilling large amounts of these danger
signals, migration pathways need to be turned off and the
reparitive programs turned on. Transfection of hMSCs with the
dominant negative expressing TLR3 and TLR4 plasmids
diminished migration by .50% in unstimulated hMSCs as
expected. However, poly(I:C) or LPS stimulation of these
transfected cells resulted in further enhancement of migration
when compared with unstimulated controls (data not shown). We
speculate that specific TLR3 or TLR4 receptor inhibition by the
transfected dominant negative expressing plasmids de-represses
chemokine or other chemotactic receptors’ inhibition downstream
from these receptors while potentiating alternative poly(I:C) or
LPS receptors. One potential mechanism that we are currently
pursuing to explain this finding is mediated by the suppressors of
cytokine signalling (SOCS)1 and SOCS3 within hMSCs. TLR3
stimulation triggers a JAK/STAT signaling cascade indirectly by
its induction of type I-interferons resulting in the activation of
SOCS 1 and 3. The activation of these proteins downregulate the
expression of the chemokine receptor, CXCR4, altering CXCR4-
CXCR7-dependent migration of hMSCs. Our study suggests a
new role for SOCS, CXCR4, and CXCR7 in hMSC migration (S.
Tomchuck unpublished observation).
We hypothesize that polarization of hMSCs by TLR-priming
also affects their programming towards tri-lineage differentiation,
and that the various reported contrasting effects might also be
explained by differences of source, amount, and time of incubation
with the TLR-agonists during the induction periods. We measured
the effect on hMSC differentiation with our low level TLR
agonists maintained for the duration of the induction of hMSC
differentiation, and again found evidence that TLR3 and TLR4
have divergent effects on hMSCs. By these methods, we report
that TLR3 activation inhibited all of the tri-lineage programs
(Fig. 3). TLR4 stimulation of hMSCs inhibited adipogenesis,
stimulated osteogenesis, and did not affect chondrogenesis. Others
have reported that murine MSCs activation of TLR2 inhibited
both differentiation and migration of muMSCs [14]. Liotta et al.
Figure 7. Jagged 1 and Jagged 2 expression in hMSCs. A. Data show that Jagged 1 expression is elevated, perinuclear, and focused
on edges in TLR4-primed but not TLR3-primed hMSCs. Yellow arrows point to corresponding magnified cell nuclei. B. Jagged 2
expression is diffuse in TLR3-primed hMSCS, increased, and perinuclear and endosomal after TLR4 stimulation of hMSCs. Methods:
hMSCs were grown on chamber slides to 70% confluence TLR-primed as before and incubated further for 24 hr prior to fixation. Jagged 1 and Jagged
2 antibody staining was performed as indicated in Methods. Representative micrographs of 5 tested hMSC donors.
doi:10.1371/journal.pone.0010088.g007
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chondrogenic differentiation in hMSCs [21]. Further, in contrast
to our study, their report suggested equivalent roles for TLR3 and
TLR4 engagement in hMSC immune modulation. Recently,
Lombardo et al. reported that TLR3 and TLR4 engagement
within hADSCs increased osteogenic differentiation but had no
effect on their adipogenic differentiation or proliferation [22].
They also report that TLR2, TLR3, and TLR4 ligation does not
affect hADSCs ability to suppress lymphocyte activation, in
contrast to the Liotta et al. report. From these various studies,
we argue that specific TLR activation affects many aspects guiding
stem cell fates, but unfortunately a consensus on the effect of TLR
stimulation and tri-lineage differentiation of stem cells is not
possible since some of the experimental details of others’ studies
were not always included.
Apart from the effects on differentiation, the TLR-priming
protocol affected the ability of hMSCs to deposit ECM, another
established classical function of these cells. Unlike unprimed
hMSCs and TLR4-primed hMSCs that deposited more collagen,
TLR3-primed hMSCs deposited more fibronectin (Fig. 4). To help
explain these results, we next evaluated TGFb as an established
component of mechanisms that control ECM deposition, and
because it is also linked to immune modulation [40,41,48]. Indeed,
we found that TGFb, SMAD3, and SMAD7 were affected by
TLR-priming of hMSCs (Fig 5 and 6). As expected, enhanced
collagen deposition in TLR4-primed hMSCs correlated with
TGFb expression and activation of its downstream signals
(phosphoSMAD3). By contrast, TLR3-primed hMSCs that
deposited greater levels of fibronectin had decreased TGFb1 and
3 expression and increased SMAD7 (TGFb signaling inhibitor)
expression. Although we would expect that TGFb, an immunor-
egulating factor, would be associated with the TLR3-primed
phenotype rather than the pro-inflammatory TLR4-primed one, it
is likely that TGFb plays a smaller role in hMSC immunomod-
ulation than for immune cells. Immune modulatory mechanisms
of hMSCs may rely more on local IL10 receptor mechanisms as
recently illustrated [24,49,50]. Immunomodulation mechanisms
controlled by TGFb appear very complicated, and like TLR-
signaling achieve their effects dependent on specific cellular
context. For instance, in a recent study, investigators sought to
quell inflammation in the brain by manipulation of TGFb and
SMAD3 in immune cells as a new method to prevent Alzheimer’s
disease. Their strategy surprisingly increased macrophage infiltra-
tion in the brain periphery in direct contrast to their original
hypothesis, but fortuitously these cells more effectively cleared
amyloid plaques [51].
The TGFb immune dampening effects are also associated with
the reprogramming of T-lymphocyte effector cells towards
immunosuppressive T-regulatory cells (T-regs). TGFb cooperates
with members of the Notch1 family to regulate the critical
transcription factor (Foxp3) to favor Tregs. Additionally, hMSCs
are known to recruit and support T-regs as part of their
immunedampening effects [52,53]. TLR3 and TLR4 signaling
within MSCs were recently shown to downregulate the Notch1
receptor family member, Jagged 1, and by this method to inhibit
T-cell suppression by MSCs [21]. By contrast, we found that by
our TLR-priming protocol, Jagged1 expression was elevated in
TLR4-primed hMSCs, and dampened only in unprimed or
TLR3-primed hMSCs. We speculate that varied concentrations
and time of incubations with the TLR-agonists might help explain
these differences. Apart from the distinct TLR-driven migration
and soluble immune modulators’ effects of hMSCs, we observed
differences in the expression of IDO and PGE2 secretion (Fig. 8).
TLR3-primed hMSCs elaborated elevated levels of both of these
when compared with unprimed or TLR4-primed hMSCs. These
observations lend further support for our proposed polarization
scheme. We are currently evaluating the effect of these mediators
in the context of immune responses that TLR-primed hMSCs
affect.
We did investigate the immune modulating effect by the TLR-
primed cells on T-lymphocyte activation (Fig. 9). In light of the
conflicting reports noted above on the effect of TLR3 and TLR4
stimulation on MSCs’ ability to suppress T-lymphocyte activation,
it was of interest to see what effects our TLR-priming protocol had
on this hMSC function. Critical to the main premise of this study,
we found that TLR4-primed hMSCs behaved as Liotta et al.
reported, and inhibited the recognized MSC suppression of T-
lymphocyte activation. While in our hands, TLR3-primed hMSCs
and unprimed MSCs suppressed T-lymphocyte activation, as
expected. Consistent with our proposed new polarization MSC
paradigm, TLR4-primed hMSCs (MSC1) would support a pro-
inflammatory environment including the T-effector cells found in
that environment whereas TLR3-primed MSC2 would favor an
immunosuppressive one. In support of this assertion, we have
treated murine models of inflammatory lung injury with our MSC1
and MSC2 cells, and found by several parameters that, as
expected, MSC1 treatment aggravated the inflammatory injury,
Figure 8. MSC1 differ from MSC2 in their expression of
inflammatory mediators. The data show increased expression
of known immune suppressive effectors like indoleamine 2,3-
dioxygenase (IDO) and prostaglandin E2 (PGE2) by TLR3-
primed but not TLR4-primed hMSCs. Methods: MSCs were pre-
treated for 1 hr with TLR agonists (LPS for MSC1 or poly(I:C) for MSC2),
washed, and cultured for an additional 48 hr prior to harvesting the
spent medium for PGE2 detection. PGE2 was measured with commer-
cially available ELISA assays (Cayman Chemical, MA). For IDO
measurement, MSCs were primed as described, incubated another
6 hr prior to harvesting the RNA and real time PCR assay. Data are
presented by the quantitative comparative CT (threshold value) method
[56]. Error bars indicate SEM. n.3 with at least 4 different hMSC donors.
doi:10.1371/journal.pone.0010088.g008
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hMSC treatments (Dr. Deborah Sullivan unpublished observa-
tions). For the T-lymphocyte activation set of experiments, we
performed the classical allogeneic co-cultures with direct contact
between hMSC-hPBMCs. We did not address the potential of
soluble mediators alone in this context. For human-derived MSCs
cell-cell contact appears to be essential to their immunomodula-
tory mechanisms [31,50]. Indeed, we found contact-dependent
secretion by hMSCs of CCL10 (IP-10), CCL5 (RANTES), HGF,
and GM-CSF in third party co-cultures with ovarian cancer cell
lines and hMSCs (data not shown). We also noted that in the direct
cell contact co-cultures performed here, the secretions of these
factors followed the same trends, and are consistent with those
reported for the hMSCs cultured alone. This finding does not
readily explain the contrasting effects by the TLR-primed hMSCs
on T-lymphocyte proliferation since we did not measure IL2 levels
or other potential T-cell activating factors. More information
regarding these effects may be gained from animal disease models
where both MSCs and leukocytes (PBMCs) interact and can be
more directly tested. Alternatively, a better handle on the
molecular details for the important contributions of each TLR-
primed cell may be provided in studies using individually marked
cell compartments specifically knocked-out for distinct genes.
Interestingly, we noted that in these assays TLR4-primed
hMSCs were more readily coated with the round hPBMCs, when
compared with unprimed or TLR3-primed hMSCs, in the co-
culture assays, after overnight incubation, and throughout the
experiment as seen through microscopy. The cell count for this
sample group was always greater than that for the other two
sample groups (Table 1). We have not investigated the significance
of this observation but it goes along with an increase in this sample
group of T-cell activation as reported in Fig 9. Our current efforts
are focused on determining the specific T-lymphocyte and
monocyte effects by the TLR-primed MSCs. Other reports have
demonstrated direct cell contact-dependent effects by MSCs to
modulate antigen-presenting cells [31,49,50]. We aim to extend
Figure 9. MSC1 support PBMC (T cell) activation, while unprimed MSCs and MSC2 suppress it. The data show differences (red
arrows) in T cell activation when allogeneic PBMCs are stimulated (PBMCs*), and co-cultured with untreated MSCs (A), MSC1 (B) or
MSC2 (C). 9D and 9E. Expression of Jagged 1 and SMAD7 in MLMR co-culture assays. There is elevated Jagged 1 expression in
MLMR assays with MSC1 (TLR4-primed), when compared to MSC2 (TLR3-primed), and unprimed assay cultures. By contrast, there
is elevated SMAD7 expression in MSC2, when compared to MSC1, and unprimed assay cultures. 9D. Expression of Jagged 1 and
SMAD7 among the CD45+ non-adherent hPBMCs collected at the end of the MLMR experiments. 9E. Expression of Jagged 1 and
SMAD7 among the CD90+ adherent hMSCs collected at the end of the MLMR experiments. Methods: T cells among the peripheral blood
mononuclear cells (PBMCs) were activated with 1 mg of CD3/CD28 antibody beads, prior to labeling with fluorescence label (CFSE), to monitor their
activation or cell division, and loaded at a 10:1 ratio over the hMSCs. The hMSCs were untreated, primed for 1 hr with TLR-4 (MSC1), or TLR3 (MSC2)
agonist, washed in medium, and loaded with the PBMCs. After greater than 72 hr of co-culture, the CFSE-labeled PBMCs were harvested from the
adherent MSCs, stained with propidium iodide to gate for live cells, and measured by flow cytometry. Unstained cells and PBMCs not activated with
antibodies served as controls in the assay. Data are expressed as change from the % T cell activation obtained for CD3/CD28 antibody –activated
PBMCs not co-cultured with MSCs=100. Error bars indicate SEM. Data are averages of triplicate determinations with 5 MSC donors and 2 PBMC
donors.
doi:10.1371/journal.pone.0010088.g009
TLR Polarization of MSCs
PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e10088these observations with the effect of TLR-primed, or polarized,
MSC1 and MSC2, on both macrophages and T-lymphocytes.
Cell-contact dependent Jagged 1 and SMAD7 expression in the
co-cultures correlated with the effects observed for the TLR-
primed hMSCs alone (Fig. 7 and 9). The significance of these
findings remains to be explored in the studies mentioned above.
Finally, we speculate that until now only an immunosuppressive
phenotype has been recognized for current heterogeneous MSC
preparations because of the manner in which they are isolated
from the host and the way they are expanded in ex vivo culture. We
reason that the default MSC phenotype must be an immunosup-
pressive one in order to avoid profound and deleterious
consequences from a pro-inflammatory MSC1 phenotype in the
context of the hematopoetic stem cells (HSCs) that MSCs maintain
and support within the progenitor/stem cell niches both of these
cells share. We envision that circulating or quiescent stem/
progenitor cells are equipped to respond to environmental cues
but must not be actively engaging immune cells or repair cells
while circulating throughout the body or maintaining HSCs in the
bone marrow niche. In a manner analogous to the immature state
maintained for monocytes, dendritic cells, and other immune cells
until a response is needed, MSCs are immunosuppressive until a
pro-inflammatory role is essential to promote tissue repair. We also
surmise that TLR4-priming is not the optimal way to induce the
MSC1 phenotype. It is likely that a combination of other factors
like interferons or contact with other pro-inflammatory cells and
their microenvironments along the lines of that reported by
Romieu-Mourez et al. will more readily induce the MSC1
phenotype [47]. Current efforts in the lab are aimed at further
defining the MSC1 and MSC2 phenotypes by a comprehensive
gene array analyses that will lead to greater clues and more
optimal marshalling of the heterogeneous MSC preparations into
these two newly defined phenotypes.
In summary, we found that hMSCs polarize into two distinctly
acting phenotypes following specific TLR-activation. TLR3-
priming specifically leads to enhanced fibronectin deposition,
expression of immune dampening mediators, and maintained
suppression of T-cell activation. By contrast, TLR4-priming
results in collagen deposition, expression of pro-inflammatory
mediators, and a reversal of the MSC-established suppressive
mechanisms of T-cell activation. Our study challenges current
dogma that infused MSCs are only immunosuppressive, and
instead suggests that they have more complex immune modulating
activity. These findings also provide an explanation for some of the
conflicting reports on TLR-activation and its consequence on the
immune modulation by stem cells. We also recognize that hMSCs
have many cell fates and that this newly described polarizing
potential represents an interesting paradigm worthy of further
study. In a manner similar to the monocyte field, we caution that
although polarization is a convenient way to better define a
heterogeneous population of cells that may help in the studying of
them, it is not an absolute fate of these cells. We aim to expand the
current understanding of MSC biology with these newly defined
phenotypes, and to also offer guidance in the improved design of
current MSC-based therapies.
Materials and Methods
MSCs
Primary human MSCs (hMSCs) were obtained from our
collaborators at the Tulane University Center for Gene Therapy.
Additionally, hMSCs were obtained from Lonza (Walkersville,
MD) to ensure variability of the starting cell population, and to
make certain that findings are universal and not unique to single
donor pools derived from a unique source, as described [15]. All of
the MSC donor preparations from these sources are tested for
hematopoetic stem cell markers by the sources and in our lab. All
the MSC preparations used in this study are less than 1% positive
for CD34 and CD45. MSCs of a passage number no greater than
4 are used in all the experiments to maintain consistency. Also, no
less than 5 different unrelated donor MSC pools were tested in all
experiments. MSCs from unique donors were tested individually
and never pooled with other donors throughout our study.
TLR Priming Protocol
In this study, LPS (10 ng/mL, Sigma-Aldrich, St. Louis, MO)
and poly(I:C) (1 mg/mL, Sigma-Aldrich) were used as the agonists
for TLR4 and TLR3, respectively, as described [15]. Typically,
hMSCs are grown to 60–70% confluency in growth medium
(DMEM-alpha and 16.5% FCS) prior to the start of an
experiment. TLR-agonists are added to fresh growth medium
and incubated with the cells for 1 hr. Then the cells are washed
twice in growth medium without the TLR-agonists and assayed as
described for the experiments. Please note that we believe based on our
observations that short incubation (,1 hr) and minimal TLR agonist
exposure at concentrations noted above (or less) are essential to arrive at these
phenotypes—which mimic the gradient of danger signals endogenous MSCs
encounter and respond to at a distance from the site of injury.
LPS Contamination
Rigorous testing for LPS contamination is routinely performed
on all the reagents used in this study to avoid spurious conclusions
due to this potential TLR-agonist contaminant (Limulus amebo-
cyte lysate chromogenic endpoint assay, Hycult Biotechnologies,
The Netherlands). Additionally, all reagents are aliquoted for
single or minimal use portions to prevent contamination.
TLR3 and TLR4 inhibition
hMSCs were grown to 70% confluence, harvested, then
transfected with pZERO-hTLR3 and pZERO-hTLR4 (Invivo-
gen), using 250 ng plasmid/1610
6 cells (nucleofector). 50 ng
pMAX-GFP was transfected alone for control and co-transfected
Table 1. Cell counts after hMSC-PBMC co-cultures.
MSCs
Primed
TLR
Leukocyte
activation PBMCs, d1 PBMCs, d2
-- + 50,000+/21784 30,000+/21774
MSCs, d1 - + 40,000+/21352 30,000+/21980
MSC1, d1 TLR4 + 70,000+/23234 80,000+/25976
MSC2, d1 TLR3 + 35,000+/21122 33,000+/21444
MSCs, d2 - + 50,000+/22354 40,000+/21730
MSC1, d2 TLR4 + 70,000+/24376 80,000+/26118
MSC2, d2 TLR3 + 30,000+/22974 32,000+/21750
Allogeneic co-culture assays reveal that TLR4 priming of hMSCs (MSC1)
promotes T-cell proliferation, while unprimed hMSCs and TLR3 primed hMSCs
(MSC2) suppress it. Methods: T cells among the peripheral blood mononuclear
cells (PBMCs) were activated with 1 mg of CD3/CD28 antibody beads prior to
labeling with fluorescence label (CFSE) to monitor their activation or cell
division and loaded at a 10:1 ratio over the MSCs for 72 hr. For cell counts, an
aliquot of the 72 hr spent medium was removed prior to flow cytometry for
Trypan Blue staining and counting as standard. Data are representative of four
independent experiments and are expressed as mean cell counts +/2SEM of 4
replicate counts on a hemocytometer after trypan blue staining. Total of 5 MSC
donors and 5 PBMC donors were used in the assay. Two representative donors
(d1, d2) are shown.
doi:10.1371/journal.pone.0010088.t001
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transfection was plated across half of a 24-well plate and allowed to
recover for 48 hr. Cells from each transfection were left untreated
or stimulated with TLR3 and TLR4 agonists for 1 hr, washed,
and incubated for 48 hr. Conditioned medium was harvested and
stored at 280uC until analysis. Transfection efficiency was also
monitored by co-transfection with 500 ng NF-kB-promoter driven
luciferase (LUC)-expressing plasmid (Stratagene/Agilent Technol-
ogies LaJolla, CA). Transfection efficiency was determined by
these methods to be 30–35% of the cells.
BioPlex Assays
MSCs were plated at a density of 5610
4 in 24-well plates,
allowed to adhere overnight, then primed with TLR agonists for
1 hr as indicated. Conditioned medium was collected after 48 hr
and analyzed with Bio-Plex Cytokine Assays (Human Group I &
II; Bio-Rad, Hercules, CA) following the manufacturer’s instruc-
tions. These experiments were performed at least three times on
three individual MSC donor pools.
Transwell Migration/Invasion assay
Migration assays were performed in transwell inserts with 8-mm
pore membrane filters pre-coated with growth factor-reduced
Matrigel
TM layer to mimic basement membranes [15,54]. TLR-
primed or unprimed cells were grown to subconfluence (70%)
prior to harvesting by trypsinization and labeling with CellTrack-
er
TM green (1 mM, Molecular Probes, Eugene, OR) for 1 hr at
37uC. Fluorescently labeled hMSCs (2.5 to 5610
5 cells/well in
300 mL) were loaded onto the upper chamber, and 500 mL
hMSCs growth medium was loaded onto the bottom chamber.
After overnight incubation the upper side of the filters was
carefully washed with cold PBS and non-migrating cells remaining
were removed with a cotton tip applicator. Fluorescence images of
the migrating cells were collected using a Nikon TE300 inverted
epifluorescence microscope (DP Controller v1.2.1.108, Olympus
Optical Company, LTD; Nikon USA, Lewisville, TX). Each
experiment was performed in triplicate with five separate hMSCs
donors. Data are expressed as numbers of counted, migrated cells
per 200X field micrograph for each sample well, and normalized
to those cell counts obtained for the untreated control.
hMSC Tri-lineage Differentiation Protocols
Modified from [55].
Chondrogenic Differentiation
hMSCs (2.5610
5) were placed into defined chondrogenic
medium and gently centrifuged (8006g for 5 minutes) in a 15 mL
conicaltubewheretheyconsolidatedinto a cellmassorpelletwithin
24 hours. Chondrogenic medium (CM) consists of high glucose
(4.5 g/L) DMEM supplemented with ITS+1 (6.25 mg/mL insulin,
6.2 mg/mL transferrin, 6.25 mg/mL selenous acid, 5.33 mg/mL
linoleic acid, 1.25 mg/mL bovine serum albumin), 0.1 mM
dexamethasone, 10 ng/mL TGF-b3, 50 mg/mL ascorbate 2-
phosphate, 2 mM pyruvate, and antibiotics. TGF- b 3 is prepared
fresh from lyophilized powder, and CM in cultures is replaced every
third day. At harvest, the samples are fixed in 10% neutral buffered
formalin for several hours, and then processed and embedded in
paraffin. Sections of chondrogenic pellets were stained with
Safranin O to detect the accumulation of proteoglycans.
Osteogenic Differentiation
hMSCs are cultured at 3610
4 cells/well in 6-well plates in
growth medium to 70% confluency, then the medium is replaced
with medium containing osteogenic supplements (OS). OS consists
of 50 mM ascorbate 2-phosphate, 10 mM b-glycerol phosphate,
and 10
28 M dexamethasone. After three weeks cells are fixed and
stained with 40 mM Alizarin Red (pH 4.1) to visualize calcium
deposition in the ECM for 10 minutes.
Adipogenic Differentiation
Adipogenic induction medium (MDI+I medium): 1 mM Dexa-
methasone and 0.5 mM methyl-isobutylxanthine, 10 mg/mL
insulin, 100 mM indomethacin, and 10% FBS in DMEM (4.5 g/
L glucose) is added to the confluent layer of hMSCs for 48–72 hr.
The medium was then changed to adipogenic maintenance
medium for 24 hours. Adipogenic maintenance (AM medium)
contains 10 mg/mL insulin and 10% FBS in DMEM (4.5 g/L
glucose). The cells are treated twice more with MDI+I for a total
of three treatments. The cells were washed with PBS and fixed in
10% formalin for 1 h at 4uC, stained for 10–15 minutes at room
temperature with a working solution of Oil Red O stain, then
rinsed 3x with distilled water.
Flow cytometry
Human MSCs were harvested and analyzed by flow cytometry
with a BD-FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA) as described previously [54]. Intracellular antibody
staining was achieved after fixation and permeabilization of the
cells as indicated by the manufacturer (cytofix/cytoperm buffers,
BD Biosciences, San Jose, CA). Isotype controls and untreated or
unstained samples were run in parallel, as standard. Analysis of
MSC donor pools was performed on a BD-FACSCAlibur (BD
Biosciences, San Jose, CA) using BD CellQuest Pro software.
Multi-color flow cytometry analysis was performed on a BD LSRII
analyzer and analyzed with CellQuest software.
Primary antibodies: Isotype-control FITC mouse IgG1K; isotype-
control PE mouse IgG1K; isotype-control mouse IgG1K; anti-
CD105; -CD166; -CD90; -CD44;-CD34; -CD31; -CD106
(BDBiosciences); -CD45, -CD3, -CD4, - CD8, -CD14, -CD15, -
CD19, -CD36, -CD56, -CD123, 235a (eBiosciences), -SMAD3, -
phosphoSMAD3, -SMAD7, -JAGGED1 and -JAGGED2 (Cell
Signaling Technologies, R&D Biosystems, and Santa Cruz
Biotechnologies); b Actin (Sigma-Aldrich, MO, #A-2066).
Fluorescence Immunocytochemical Analysis (IF)
IF was performed on fixed and permeabilized cells on chamber
slides, as before [54]. The primary antibodies were diluted at
appropriate concentrations (ratio of 0.5 mg Ab/1610
6 cells) and
visualized, as standard. Omission of primary antibodies served as
negative controls. Micrographs were taken on a Nikon TE300
inverted epifluorescence microscope. Data were presented as
stained micrographs and quantified by ImageJ software densitom-
etry analysis from at least three similarly stained sections.
Transforming growth factor b (TGF)1, 2, and 3 Assays
TGFb secretion was measured from the conditioned medium by
luminex immunoassay as per manufacturer’s recommendations
(LuminexH Bead immunoassay Kit, LINCOplex from Millipore).
The MSCs were pre-treated for 1 hr with LPS or poly(I:C),
washed, and cultured for an additional 48 hr prior to harvesting
the spent medium for TGFb detection.
Indoleamine 2,3-dioxygenase (IDO) Assay
IDO was measured by real-time PCR analysis of RNA
extracted from TLR-primed MSCs incubated for an additional
6 hr prior to RNA harvest. Data are presented by the quantitative
TLR Polarization of MSCs
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[46].
HLA-G expression
HLA-G was detected by both western blot analysis and flow
cytometry. Western blot with an anti-HLA-G antibody (clone
4H84), and flow cytometry of both membrane and intracytoplas-
mic molecules were detected with FITC-conjugated Ab directed
against anti-HLA-G1/-G5 isoforms (clone MEM-G/9) or HLA-
G5 (clone 5A6G7), respectively, as before [33].
Prostaglandin E2 (PGE2) Assay
PGE2 was measured from the spent culture medium after 1 hr
TLR-agonist priming, wash, and 48 hrs of subsequent culture in
growth medium by commercially available ELISA assays (Cayman
Chemical, MA).
Allogeneic mixed lymphocyte and MSC reactions (MLMR)
A variation on published methods was used here to assess
alloreactive T-cell proliferation [3,32]. Human peripheral blood
mononuclear cells (PBMCs) were prepared from leucopheresis
packs (The Blood Center, New Orleans, LA) by standard
centrifugation on a Ficoll Hypaque density gradient. Ten million
CFSE-labeled-PBMCs (from at least 5 unrelated donors, Molec-
ular Probes) in the presence or absence of the isolated TLR-
primed MSCs or unprimed MSCs were resuspended and
stimulated with 1 mg of CD3/CD28 antibody beads (Sigma, St.
Louis, MO) at a 10:1 ratio. After 72 hr, an aliquot was removed
for cell counting with trypan blue exclusion as standard and the
remainder of the non-adherent cells were then stained with anti-
CD8 or CD4 antibody, and the CFSE dilution of the CD8+ cells
assessed by flow cytometry analysis (eBiosciences). No less than
100,000 events/sample were collected. Cell surface marker
expression of CD4/CD8 was assessed and quantified in arbitrary
units as mean fluorescence intensity (MFI) of a live population of
cells (propidium iodide negative) labeled with a fluorescence-
conjugated monoclonal Ab (eBiosciences).
Statistical Analysis
Typically, data were represented as average +/2 standard error
of the mean (S.E.M.). Multiple group comparisons were
performed by one-way analysis of variance (ANOVA) followed
by the Bonferroni procedure for comparison of means. Compar-
ison between any two groups was analyzed by the two-tailed
Student’s t-test or two-way ANOVA (Prism4, GraphPad Software
Inc. CA). Values of p,0.05 were considered statistically
significant.
Supporting Information
Table S1 TLR-regulated gene cDNA arrays. The effect of TLR
stimulation on gene expression within hMSCs was analyzed by
TLR-pathway focused cDNA array (see ‘‘http://www.superarray.
com/genetable.php?pcatn=APHS-018A’’ for details on the
arrayed genes). Results are presented as fold changes in gene
expression of TLR-primed MSC1 and MSC2 relative to unprimed
hMSCs for 6 different donors partially reported in [15].
Found at: doi:10.1371/journal.pone.0010088.s001 (0.15 MB
RTF)
Table S2 BioPlex Human Cytokine, chemokine and growth
factor assays. The hMSCs were pre-treated for 1 hr with TLR
agonists (LPS for MSC1 or poly(I:C) for MSC2), washed and
cultured for an additional 48 hr prior to harvesting the spent
medium and analysis with Bio-Plex Cytokine Assays following the
manufacturer’s instructions. Data are expressed in average pg/mL
obtained from corrected triplicate measurements with at least 3
MSC donors in four independent experiments. Dominant negative
transfected plasmids used were pZero-TLR3 (p0-TLR3) and
pZero-TLR4 (p0-TLR4, InvivoGen, San Diego, CA).
Found at: doi:10.1371/journal.pone.0010088.s002 (0.08 MB
RTF)
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